首页> 美国卫生研究院文献>Current Oncology >Astragalus-containing Traditional Chinese Medicine with and without prescription based on syndrome differentiation combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis
【2h】

Astragalus-containing Traditional Chinese Medicine with and without prescription based on syndrome differentiation combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis

机译:含黄芪的中药有或没有基于辨证论治的处方联合化疗治疗晚期非小细胞肺癌:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectiveTraditional Chinese Medicine (tcm) is used in China as part of the treatment for non-small-cell lung cancer (nsclc) and often includes prescription of herbal therapy based on syndrome differentiation. Studies of various Astragalus-based Chinese medicines combined with platinum-based chemotherapy in the treatment of lung cancer are popular in East Asia, particularly in China. The aim of the present study was to perform a systematic review and meta-analysis comparing platinum-based chemotherapy alone with platinum-based chemotherapy plus Astragalus-based Chinese botanicals, with and without prescription based on syndrome differentiation, as first-line treatment for advanced nsclc.
机译:目的传统中药(tcm)在中国被用作非小细胞肺癌(nsclc)治疗的一部分,并且通常包括基于辨证论治的草药疗法处方。在东亚,尤其是在中国,对多种基于黄芪的中药与铂类化学疗法联合治疗肺癌的研究很受欢迎。本研究的目的是进行系统评价和荟萃分析,比较以铂为基础的化学疗法与以铂为基础的化学疗法加上以黄芪为基础的中国植物药(有或没有基于证候分化的处方)作为晚期一线治疗的情况。 nsclc。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号